HELP Stock Chart & Stats
$5.50
-$0.06(-0.78%)
At close: 4:00 PM EST
$5.50
-$0.06(-0.78%)
Day’s Range― - ―
52-Week Range$3.76 - $11.62
Previous Close$7.77
Volume369.09K
Average Volume (3M)1.67M
Market Cap
$1.38M
Enterprise Value$0.00
Total Cash (Recent Filing)$116.53M
Total Debt (Recent Filing)$40.19M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.01
Shares Outstanding61,984,077
10 Day Avg. Volume2,162,578
30 Day Avg. Volume1,673,573
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)7.14
Price to Sales (P/S)0.00
P/FCF Ratio-16.39
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$35.33Price Target Upside542.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Helus Pharma News
HELP FAQ
What was Helus Pharma’s price range in the past 12 months?
Helus Pharma lowest stock price was $3.76 and its highest was $11.62 in the past 12 months.
What is Helus Pharma’s market cap?
Helus Pharma’s market cap is $1.38M.
When is Helus Pharma’s upcoming earnings report date?
Helus Pharma’s upcoming earnings report date is Nov 16, 2026 which is in 96 days.
How were Helus Pharma’s earnings last quarter?
Currently, no data Available
Is Helus Pharma overvalued?
According to Wall Street analysts Helus Pharma’s price is currently Undervalued.
Does Helus Pharma pay dividends?
Helus Pharma does not currently pay dividends.
What is Helus Pharma’s EPS estimate?
Helus Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helus Pharma have?
Helus Pharma has 61,984,077 shares outstanding.
What happened to Helus Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Helus Pharma?
Currently, no hedge funds are holding shares in HELP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helus Pharma
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
HELP Stock 12 Month Forecast
Average Price Target
$35.33
▲(542.42% Upside)
Ownership Overview
12.99% Insiders
2.89% Other Institutional Investors
83.52% Public Companies and Individual Investors